Fusion Pharmaceuticals Inc.
Fusion Pharmaceuticals Inc. (FUSN) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · FUSN · as of Mar 31, 2024
Ownership Breakdown
140
Institutional Holders
▲ 57 vs Q4
$1.47B
Total Inst. Value
▲ $888.91M vs Q4
85.06M
Shares Outstanding
freeFloat 72.39%
69.09M
13F Shares Held
▲ 8.29M vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
FUSN largest shareholders · institutional ownership
Q1 2024 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
FEDERATED HERMES, INC. biological products, (no diagnostic substances) | 10.81M | 14.79% | 14.79% | $230.49B | May 14, 2024 | ▼ 75.0K |
PERCEPTIVE ADVISORS LLC biological products, (no diagnostic substances) | 6.83M | 9.34% | 9.34% | $145.52B | Aug 6, 2024 | ▲ 4.07M |
AVIDITY PARTNERS MANAGEMENT LP biological products, (no diagnostic substances) | 6.50M | 8.89% | 8.89% | $138.59B | May 15, 2024 | — held |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) biological products, (no diagnostic substances) | 6.40M | 8.76% | 8.76% | $136.47B | May 15, 2024 | — held |
FIL LTD biological products, (no diagnostic substances) | 4.19M | 5.73% | 5.73% | $89.27B | May 13, 2024 | NEW |
PENTWATER CAPITAL MANAGEMENT LP biological products, (no diagnostic substances) | 3.78M | 5.17% | 5.17% | $80.63B | May 15, 2024 | NEW |
JOHNSON & JOHNSON biological products, (no diagnostic substances) | 3.67M | 5.02% | 5.02% | $78.26B | May 10, 2024 | — held |
CANADA PENSION PLAN INVESTMENT BOARD biological products, (no diagnostic substances) | 3.12M | 4.26% | 4.26% | $66.45B | May 14, 2024 | — held |
TPG GP A, LLC biological products, (no diagnostic substances) | 2.55M | 3.49% | 3.49% | $54.40B | Aug 14, 2024 | — held |
FMR LLC biological products, (no diagnostic substances) | 1.84M | 2.51% | 2.51% | $39.16B | May 13, 2024 | ▼ 3.48M |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2024 vs prior quarter
Q1 2024
14
Increased
+9.28M shares22
New Positions
first time holders7
Decreased
−5.55M shares0
Sold Out
fully exitedNet shares change (top 50)
+3.73M
+9.28M / −5.55M
Net new holders
+29
22 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
FUSN insider trading · insider activity
Source: SEC Form 4
0
Buy transactions
69
Sell transactions
0.00
Buy/Sell ratio
$9M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Bitetti Teresa Marie director | Jun 4, 2024 | D-Return | 34,000 | $4.16 | $141.4K | 0 | Form 4 ↗ |
GANNON STEVEN director | Jun 4, 2024 | D-Return | 56,400 | $21.00 | $1.18M | 0 | Form 4 ↗ |
GANNON STEVEN director | Jun 4, 2024 | D-Return | 17,000 | $3.60 | $61.2K | 0 | Form 4 ↗ |
GANNON STEVEN director | Jun 4, 2024 | D-Return | 17,000 | $4.64 | $78.9K | 0 | Form 4 ↗ |
GANNON STEVEN director | Jun 4, 2024 | D-Return | 17,000 | $8.15 | $138.6K | 0 | Form 4 ↗ |
GANNON STEVEN director | Jun 4, 2024 | D-Return | 141,011 | $2.35 | $331.4K | 0 | Form 4 ↗ |
GANNON STEVEN director | Jun 4, 2024 | D-Return | 30,000 | $17.00 | $510.0K | 0 | Form 4 ↗ |
Valliant John Chief Executive Officer | Jun 4, 2024 | D-Return | 192,200 | — | — | 0 | Form 4 ↗ |
Valliant John Chief Executive Officer | Jun 4, 2024 | D-Return | 336,000 | $11.90 | $4.00M | 0 | Form 4 ↗ |
Valliant John Chief Executive Officer | Jun 4, 2024 | D-Return | 500,000 | $3.75 | $1.88M | 0 | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Fusion Pharmaceuticals Inc. (FUSN) is primarily owned by institutional investors, who hold approximately 81.2% of total shares outstanding. Company insiders own approximately 27.61%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Fusion Pharmaceuticals Inc. is FEDERATED HERMES, INC., holding approximately 10.81 million shares — equal to 14.79% of outstanding shares — as of March 31, 2024.
A total of 140 institutional investors currently hold FUSN stock, with a combined institutional value of approximately $1.47 billion as of the most recent 13F filing period.
Frequently asked questions
FUSN ownershipFusion Pharmaceuticals Inc. (FUSN) is primarily owned by institutional investors, who hold approximately 81.2% of shares. The largest shareholder is FEDERATED HERMES, INC. with a 14.79% stake. Company insiders hold 27.61%. Data sourced from SEC Form 13F as of March 31, 2024.